NCT01975636View on ClinicalTrials.gov

An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

113

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

March 31, 2014

Conditions

Metabolism and Elimination

Interventions

DRUG

E2609

Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance

Trial Locations (2)

53704

Covance Clinical Research Unit Inc., Madison

Covance Laboratories, Madison

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT01975636 - An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter